GAITHERSBURG, Md., Sept. 07, 2016
(GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) today announced it
will host its 4th annual Investor and Analyst Meeting, Tuesday,
October 11, 2016 from 9:00 a.m. - 11:00 a.m. ET in New York,
NY.
Senior management will conduct a
series of presentations to update analysts and investors on the
Company's ongoing clinical development programs. In addition, a key
opinion leader will provide a clinical perspective on respiratory
syncytial virus (RSV) disease.
Novavax expects to announce data
from its pivotal Phase 3 trial of the RSV F Vaccine in older adults
in the third quarter of 2016.
For additional information and
registration, please email novavax@westwicke.com or call
443-213-0506.
A live webcast of the
presentations can be accessed under the "Investors"/ "Events"
section of the Novavax website at novavax.com. Please allow extra
time prior to the webcast to visit the site and download the
streaming media software required to listen to the Internet
broadcast. The webcast and a replay of the presentation will also
be accessible under the "Investors/Events" section of the Novavax
website at novavax.com. The event will be archived on the
company's website for 90 days.
About
Novavax
Novavax, Inc. (Nasdaq:NVAX) is a
clinical-stage vaccine company committed to delivering novel
products to prevent a broad range of infectious diseases. Our
recombinant nanoparticles and Matrix-M(TM) adjuvant technology are
the foundation for groundbreaking innovation that improves global
health through safe and effective vaccines. Additional information
about Novavax is available on the company's website,
novavax.com.
Contact:
Novavax, Inc.
Barclay A. Phillips
SVP, Chief Financial Officer and Treasurer
Andrea N. Flynn, Ph.D.
Associate Director, Investor Relations
ir@novavax.com
240-268-2000
Russo Partners, LLC
David Schull
Todd Davenport, Ph.D.
david.schull@russopartnersllc.com
todd.davenport@russopartnersllc.com
212-845-4271